VIA
CRNX

Virtus Investment Advisers’s Crinetics Pharmaceuticals CRNX Stock Holding History

Virtus Investment Advisers’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.26M Buy
33,736
+17,015
+102% +$632K 0.29% 166
2026
Q1 		$607K Buy
16,721
+3,186
+24% +$142K 0.17% 194
2025
Q4 		$630K Buy
13,535
+9,998
+283% +$445K 0.17% 216
2025
Q3 		$147K Buy
3,537
+614
+21% +$19.6K 0.04% 378
2025
Q2 		$84.1K Sell
2,923
-30
-1% -$926 0.03% 406
2025
Q1 		$99K Buy
+2,953
New +$110K 0.03% 422

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtus Investment Advisers's CRNX Position: Q2 2026 in Review

Virtus Investment Advisers increased its Crinetics Pharmaceuticals (CRNX) stake by 102% in Q2 2026, buying an estimated $632K and bringing the position to 33,736 shares worth $1.26M. The position accounts for 0.29% of the portfolio, ranked #166.

Virtus Investment Advisers first reported a position in CRNX in Q1 2025 and has held it in 6 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Virtus Investment Advisers held 33,736 shares of Crinetics Pharmaceuticals worth $1.26M as of Q2 2026.
  • Virtus Investment Advisers bought 17,015 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $632K.
  • Crinetics Pharmaceuticals made up 0.29% of Virtus Investment Advisers's portfolio in Q2 2026, its #166 holding.
  • Virtus Investment Advisers first reported a position in Crinetics Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.